ECA Marcellus Trust I (ECTM)
OTCMKTS · Delayed Price · Currency is USD
0.5500
-0.0400 (-6.78%)
Mar 6, 2026, 2:43 PM EST
ECA Marcellus Trust I Revenue
ECA Marcellus Trust I had revenue of $661.62K in the quarter ending September 30, 2025, with 60.36% growth. This brings the company's revenue in the last twelve months to $3.56M, up 68.22% year-over-year. In the year 2024, ECA Marcellus Trust I had annual revenue of $2.18M, down -24.60%.
Revenue (ttm)
3.56M
Revenue Growth
+68.22%
P/S Ratio
2.72
Revenue / Employee
1.78M
Employees
2
Market Cap
9.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
| Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
| Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
| Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
| Dec 31, 2020 | 1.70M | -2.44M | -58.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EXCO Resources | 394.03M |
| Unit Corporation | 246.91M |
| Trek Resources | 15.44M |
| Empire Diversified Energy | 3.64M |
| Cyber App Solutions | 586.70K |
| Surya Oil and Gas | 206.78K |
| New Green Hemp | 121.00K |
| Biloxi Marsh Lands | 46.49K |
ECA Marcellus Trust I News
- 23 days ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 1 year ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 1 year ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 1 year ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 1 year ago - Kontron introduces the XMC-ETH6 - Business Wire
- 6 years ago - ECA Marcellus Trust I Provides Update on NYSE Delisting - Business Wire